Panacea Biotec Ltd
PANA

Panacea Biotec Ltd (PANACEABIO)

₹139.60.93%

Key Stats

₹135.3
Day's Price Range
₹145
₹135
52-Week Price Range
₹449
1 Month Return-13.4 %
3 Month Return-25.53 %
1 Year Return-66.76 %

Company Financials

  • Quarterly
  • Annual
Value in ₹ crore

Peer Comparsion

PE
Rank 71
-4.04
EPS
Rank 74
₹-34.88
BVPS
Rank 79
₹-40.87
Dividend Yield
Rank 41
ROE
Rank 163
-2.46%
Price To Book Ratio
Rank 59
-3.45
Debt To Asset
Rank 5
1.17

Company Information

Indias leading researchbased health management company with established research manufacturing and marketing capabilities are collectively known as Panacea Biotec Limited PBL which was incorporated on 2nd February 1984 under the name of Panacea Drug P Ltd. A second largest vaccine producer in India has the product portfolio of highly innovative prescription products in important therapeutic areas such as pain management diabetes management renaldisease management antiosteoporosis antitubercular gastrointestinal care products and vaccines. The Company has collaborations and tieups with leading national and international research organizations and corporations. PBL has ultra modern stateofart production facilities at Himachal Pradesh Punjab Delhi for manufacturing vaccines and pharmaceutical formulations comply with the USFDA UKMHRA SAMCC and WHOcGMP standards and it has four research and development centers. The Company also has 24 product patents valid in more than 60 countries worldwide. The plant for vaccines production Radicura Pharma and pharmaceutical formulations plant Panacea Drug P Ltd at New Delhi were established during the year 1988 and 1989 respectively. In 1993 merger of Panacea Drugs P Ltd and Radicura Pharma gave the name Panacea Biotec Ltd. The Company made its Initial Public Offering IPO in the year of 1995 and also in the same year PBL had formed state of the art Drug Delivery RD centre at Lalru. In the year 1997 the company obtained its first product patent in several countries. PBLs Research Development made a tie up with European MNC in the year 2001 and in 2002 an inlicensing agreement was made with Biotechnology Consortium of India for development commercialization of Anthrax Vaccine. Also in the identical year of 2002 the company had commissioned Recombinant Vaccine production plant. During the year 2004 PBL made an inlicensing agreement with National Institute of Immunology New Delhi for Japanese Encephalitis Candidate Vaccine marketing joint venture with Chiron now Novartis Vaccines UK and also made collaboration with Cambridge Biostability UK for Thermo Stable Vaccines. After a year in 2005 an inlicensing agreement was prepared with National Institute of Health USA for Hair Growth Hormone. During the year 2006 ultra modern Pharmaceuticals formulation facility at Baddi Himachal Pradesh was goes live which has WHO cGMP complaint. Landmark collaborations were made with The Netherlands Vaccine Institute The Nederlands Vaccin Institute NVI for manufacture marketing of finished Inactivated Polio Vaccine IPV and a number of IPV based combination vaccines in India and across the globe. Collaboration was happened with PT.Bio Farma to manufacture market Measles Vaccine. Also in the same year of 2006 the company had inaugurated its Biopharmaceutical RD Centre at New Delhi and made collaboration with National Research Development Corporation NRDC for technology transfer of Foot and Mouth Vaccine. Vaccine Formulation Plant of the company was established at Baddi in the year 2007 and the research agreement was made with Punjab University to develop New Chemical Entities for Psychiatric Disorders. PBL forayed into Healthcare Delivery in the year 2008 made a collaboration to setup 220 bed multi superspecialty hospital in NCR and also the company obtained a patent Patent No. 7371412 B2 from US Patent Trademark Office for the product Thank GodTM Euphorbia Prostrata for effective management of hemorrhoids piles in the identical year of 2008.
OrganisationPanacea Biotec Ltd
HeadquartersLalru
IndustryPharmaceuticals